Thanks, I like to try to keep it real, while others constantly hype. Whether here, or there, my posts are based on what I've observed while investing in other biotechs. It's a hard lesson to learn when it comes to how much time things take. I'll be thrilled if OWCP has products on the market in the 3rd quarter, as they seem to be predicting, frankly I'll be happy if it happens this year.

I've been involved with IMGN essentially since it's been public and frankly it's been a terrible investment to date, however, I still believe it will be great and I know of no other conventional biotech that I believe has greater potential.

As for OWCP, I like the niche they're in, and especially like the people who're involved with the company in Israel. While I believe they could be clearer in what they're say in writing, I believe they're doing things the right way, and frankly avoiding the FDA in their initial products is brilliant IMHO, as long as they can market products here. Once substantial revenue develops they'll have the funding needed to run efficacy trials in the manner the FDA wants.

Gary